Given the important role of ERK8 in mediating the therapeutic efficacy of As2O3 against lung cancer cells, we suggest that As2O3 (besides its promising role in the treatment of hematologic malignancies) as a potential agent in the treatment of lung cancer patients with high ERK8 expression such that this might gain more selective killing of cancer cells. The gene discussed is MAPK15; the disease is hematologic disorder.